Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases

Reuters2026/08/05 12:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Entrada Therapeutics outlined four clinical data catalysts in 2026 across Duchenne muscular dystrophy and partnered myotonic dystrophy type 1.
ENTR-601-44 Phase 1/2 Cohort 1 at 6 mg/kg showed no serious adverse events or discontinuations; renal markers stayed within normal range.
Cohort 1 showed statistically significant improvement versus placebo in Time to Rise of 2.4 seconds, Time to Rise Velocity of 0.09 rises/second.
ENTR-601-44 Cohort 1 open-label function and safety data expected by year-end 2026; Cohort 2 at 12 mg/kg data expected in Q1 2027.
ENTR-601-45 Cohort 1 data expected in October 2026; Vertex plans to share VX-670 Phase 1/2 multiple-ascending-dose results in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Entrada Therapeutics publishes corporate presentation on genetic medicines pipeline for neuromuscular and inherited retinal diseases

You may also like

Crypto prices